Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 56

1.

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, Brachmann SM, Maira SM, Wilson C, Boehm M, Garcia-Echeverria C, Chene P, Wiesmann M, Cozens R, Lehar J, Schlegel R, Caravatti G, Hofmann F, Sellers WR.

Mol Cancer Ther. 2014 May;13(5):1117-29. doi: 10.1158/1535-7163.MCT-13-0865. Epub 2014 Mar 7.

PMID:
24608574
[PubMed - in process]
2.

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.

Gritsman K, Yuzugullu H, Von T, Yan H, Clayton L, Fritsch C, Maira SM, Hollingworth G, Choi C, Khandan T, Paktinat M, Okabe RO, Roberts TM, Zhao JJ.

J Clin Invest. 2014 Apr 1;124(4):1794-809. doi: 10.1172/JCI69927. Epub 2014 Feb 24.

PMID:
24569456
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.

Cheng H, Liu P, Zhang F, Xu E, Symonds L, Ohlson CE, Bronson RT, Maira SM, Di Tomaso E, Li J, Myers AP, Cantley LC, Mills GB, Zhao JJ.

Cancer Res. 2014 Jan 1;74(1):15-23. doi: 10.1158/0008-5472.CAN-13-0544. Epub 2013 Dec 9.

PMID:
24322983
[PubMed - indexed for MEDLINE]
4.

Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.

Wang Q, Von T, Bronson R, Ruan M, Mu W, Huang A, Maira SM, Zhao JJ.

Genes Dev. 2013 Jul 15;27(14):1568-80. doi: 10.1101/gad.216069.113.

PMID:
23873941
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.

Potiron VA, Abderrahmani R, Giang E, Chiavassa S, Di Tomaso E, Maira SM, Paris F, Supiot S.

Radiother Oncol. 2013 Jan;106(1):138-46. doi: 10.1016/j.radonc.2012.11.014. Epub 2013 Jan 12. Erratum in: Radiother Oncol. 2013 May;107(2):263. Abderrhamani, Rym [corrected to Abderrahmani, Rym].

PMID:
23321494
[PubMed - indexed for MEDLINE]
6.

Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.

Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, Signoretti S, Loda M, Zhao JJ, Roberts TM.

Cancer Discov. 2013 Jan;3(1):44-51. doi: 10.1158/2159-8290.CD-12-0262. Epub 2012 Dec 20.

PMID:
23258246
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.

Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M, Roberts TM, Sellers WR, Hofmann F, Maira SM.

PLoS One. 2012;7(8):e44146. doi: 10.1371/journal.pone.0044146. Epub 2012 Aug 31.

PMID:
22952903
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.

Brachmann SM, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJ, Kazic-Legueux M, Laborde L, Hattenberger M, Stauffer F, Vaxelaire J, Romanet V, Henry C, Murakami M, Guthy DA, Sterker D, Bergling S, Wilson C, Brümmendorf T, Fritsch C, Garcia-Echeverria C, Sellers WR, Hofmann F, Maira SM.

Mol Cancer Ther. 2012 Aug;11(8):1747-57. doi: 10.1158/1535-7163.MCT-11-1021. Epub 2012 May 31.

PMID:
22653967
[PubMed - indexed for MEDLINE]
Free Article
9.

mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.

Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, Tanaka K, Matsutani T, Iwanami A, Aronow BJ, Manway L, Maira SM, Thorgeirsson SS, Mischel PS, Thomas G, Kozma SC.

Sci Transl Med. 2012 Jun 20;4(139):139ra84. doi: 10.1126/scitranslmed.3003923. Epub 2012 Apr 25.

PMID:
22539746
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.

Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ.

Radiat Oncol. 2012 Mar 27;7:48. doi: 10.1186/1748-717X-7-48.

PMID:
22452803
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.

Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH.

PLoS One. 2012;7(2):e31331. doi: 10.1371/journal.pone.0031331. Epub 2012 Feb 15.

PMID:
22355357
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.

Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, García-Echeverría C, Sellers WR, Voliva CF.

Mol Cancer Ther. 2012 Feb;11(2):317-28. doi: 10.1158/1535-7163.MCT-11-0474. Epub 2011 Dec 21.

PMID:
22188813
[PubMed - indexed for MEDLINE]
Free Article
13.

Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature.

Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ.

Cancer Res. 2012 Jan 1;72(1):239-48. doi: 10.1158/0008-5472.CAN-11-2263. Epub 2011 Nov 22.

PMID:
22108822
[PubMed - indexed for MEDLINE]
Free Article
14.

PI3K inhibitors for cancer treatment: five years of preclinical and clinical research after BEZ235.

Maira SM.

Mol Cancer Ther. 2011 Nov;10(11):2016. doi: 10.1158/1535-7163.MCT-11-0792. No abstract available.

PMID:
22072802
[PubMed - indexed for MEDLINE]
Free Article
15.

Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.

Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK.

Clin Cancer Res. 2012 Jan 1;18(1):184-95. doi: 10.1158/1078-0432.CCR-11-1558. Epub 2011 Nov 7.

PMID:
22065080
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.

Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, González-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL.

Cancer Discov. 2011 Sep;1(4):338-51. doi: 10.1158/2159-8290.CD-11-0101. Epub 2011 Jul 20.

PMID:
22049316
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Reduced pathological angiogenesis and tumor growth in mice lacking GPR4, a proton sensing receptor.

Wyder L, Suply T, Ricoux B, Billy E, Schnell C, Baumgarten BU, Maira SM, Koelbing C, Ferretti M, Kinzel B, Müller M, Seuwen K, Ludwig MG.

Angiogenesis. 2011 Dec;14(4):533-44. doi: 10.1007/s10456-011-9238-9. Epub 2011 Nov 2.

PMID:
22045552
[PubMed - indexed for MEDLINE]
18.

Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells.

Azad A, Jackson S, Cullinane C, Natoli A, Neilsen PM, Callen DF, Maira SM, Hackl W, McArthur GA, Solomon B.

Mol Cancer Res. 2011 Dec;9(12):1696-707. doi: 10.1158/1541-7786.MCR-11-0312. Epub 2011 Oct 18.

PMID:
22009179
[PubMed - indexed for MEDLINE]
Free Article
19.

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.

Burger MT, Pecchi S, Wagman A, Ni ZJ, Knapp M, Hendrickson T, Atallah G, Pfister K, Zhang Y, Bartulis S, Frazier K, Ng S, Smith A, Verhagen J, Haznedar J, Huh K, Iwanowicz E, Xin X, Menezes D, Merritt H, Lee I, Wiesmann M, Kaufman S, Crawford K, Chin M, Bussiere D, Shoemaker K, Zaror I, Maira SM, Voliva CF.

ACS Med Chem Lett. 2011 Aug 26;2(10):774-9. doi: 10.1021/ml200156t. eCollection 2011 Oct 13.

PMID:
24900266
[PubMed]
Free PMC Article
20.

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D.

Clin Cancer Res. 2010 Nov 15;16(22):5424-35. doi: 10.1158/1078-0432.CCR-10-1102. Epub 2010 Sep 30.

PMID:
20884625
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk